BioSpace News Archive

Medivir AB announces that the company will present at the ABGSC Life Science Summit on May 18, 2022.

Vivera Biosciences is pleased to announce its collaborative progress on a Cooperative Research and Development Agreement with the National Institute of Neurological Disorders and Stroke, an Institute within the National Institutes of Health that aims to foster and advance cutting-edge neuroscience research to reduce the burden of neurological disease.

The Celiac Disease Foundation is pleased to announce the establishment of two international celiac disease research prizes.

Promore Pharma AB, reg. no. 556639-6809, held its AGM on Tuesday, 17 May 2022.

Biopharma Helico has completed an AUD $1.8 million seed funding round, attracting international interest in its plans to produce therapeutic compounds from plants and, ultimately, ‘edible medicine’.

Quotient Limited announced the opening of its new office in Dubai, UAE, and the incorporation of its subsidiary Quotient Middle-East and Africa FZ LLC, as part of its ongoing expansion plans to better support customers in the region.

Beltone, the nation’s leading hearing care retailer continuously works hard to improve the hearing of patients in the communities they serve, and announced two new opportunities that further elevate their standard of care through collaborations with Lantos Technologies and OtoSet by SafKan Health which Beltone has made available to their independent network of local business owners.

The American College of Chest Physicians and Three Lakes Foundation are announcing a steering committee of experts in the fields of pulmonary medicine and primary care medicine to lead an initiative called Bridging Specialties™: Timely Diagnosis for ILD Patients.

Rising prevalence of chronic disorders such as cancer, increasing infectious disease outbreaks such as the ongoing COVID-19 pandemic, and growing applications of miRNA in the pharmaceutical and biotechnology sectors are other key factors responsible for market growth.

Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine.